DGX Stock Analysis
DG
Avoid
Based on Eyestock quantitative analysis, DGX`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Market cap $B
17.296
Dividend yield
2.58 %
Shares outstanding
111.32 B
Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. The company is headquartered in Secaucus, New Jersey and currently employs 40,000 full-time employees. The firm operates through the DIS segment, which provides diagnostic information services to a range of customers, including patients, clinicians, hospitals, independent delivery networks (IDNs), health plans, employers, consumers, and accountable care organizations (ACOs). The company is also engaged in two business operations, Diagnostic Information Services, which develops and delivers diagnostic information services that provide insights to a range of customers, and the Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology business, which offers solutions for healthcare providers. The Company’s services are primarily provided under the Quest Diagnostics brand and also provide services under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.